Epicrew USA v. Capital Asset Exchange and Trading, LLC

District Court, N.D. California·Decided May 13, 2025·No. 5:24-cv-03676·Unknown

Opinion

EPICREW USA, Case No. 5:24-cv-03676-EJD

Plaintiff, ORDER GRANTING IN PART MOTION TO DISMISS; DENYING AS v. MOOT MOTION FOR LEAVE TO AMEND TRADING, LLC, Re: ECF Nos. 13, 31 Defendant.

Defendant Capital Asset Exchange and Trading, LLC moves to dismiss Plaintiff Epicrew USA’s complaint. Having considered the parties’ pleadings, the record, and arguments at hearing, the Court GRANTS IN PART Capital Asset’s motion WITH LEAVE TO AMEND. As such, the Court also DENIES AS MOOT Epicrew’s separate motion for leave to amend.1 Epicrew filed suit in June 2024, raising several claims arising out of Capital Asset’s alleged failure to deliver certain semiconductor equipment that Epicrew had purchased even though Epicrew had already tendered payment to Capital Asset. Compl., ECF No. 1. Capital Asset filed a motion to dismiss for failure to state a claim. MTD, ECF No. 13. After the parties finished briefing the motion, the Court held a hearing. ECF No. 26. However, because the parties had indicated the possibility of early settlement, the Court held the motion in abeyance. Hr’g Tr. at 19:25–20:11, ECF No. 32. Instead, the Court directed the parties to participate in a settlement conference with Magistrate Judge Susan van Keulen. ECF No. 27. Shortly before beginning settlement discussions, Epicrew filed a motion for leave to amend, ECF No. 31, along with a proposed amended complaint. ECF No. 31-1, Ex. A. With its motion, Epicrew sought to make two amendments. First, it sought to correct its own name, explaining that it had mistakenly named Epicrew USA as the plaintiff when it should have named Epicrew Corporation. See ECF Nos. 24, 31. Second, Epicrew sought to join three of Capital Asset’s executives. See ECF No. 31. Before the Court could address Epicrew’s motion, the parties were able to “agree[] on an overall framework for resolving this matter.” ECF No. 41. However, after further settlement discussions, the parties’ agreement eventually fell apart. ECF Nos. 45, 46. The Court therefore turns to the pending motions to dismiss and for leave to amend. A. Motion to Dismiss Capital Asset moves to dismiss for failure to state a claim under Rule 12(b)(6). To survive such a motion, the complaint must contain sufficient factual allegations to support a reasonable inference that Capital Asset is liable for Epicrew’s claims. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). To determine whether it is reasonable to make such an inference, the Court must accept all factual allegations as true and construe the complaint in Epicrew’s favor. Reese v. BP Exploration (Alaska) Inc., 643 F.3d 681, 690 (9th Cir. 2011). The Court does not, however, accept conclusory allegations or draw unreasonable inferences from the allegations. In re Gilead Scis. Sec. Litig., 536 F.3d 1049, 1055 (9th Cir. 2008) (citation omitted). In addition, for claims that sound in fraud, Rule 9(b) requires pleading with greater particularity. Namely, a plaintiff must plead “the who, what, when, where, and how” of the alleged fraud. Vess v. Ciba-Geigy Corp. USA, 317 F.3d 1097, 1106 (9th Cir. 2003) (citation omitted). B. Motion for Leave to Amend Rule 15(a) governs Epicrew’s motion for leave to amend. In these circumstances, Rule 15(a) provides that a party may “amend its pleading only with the opposing party’s written consent or the court’s leave.” Fed. R. Civ. P. 15(a)(2). Under that Rule, courts should grant leave movant, repeated failure to cure deficiencies by amendments previously allowed, undue prejudice to the opposing party by virtue of allowance of the amendment, [or] futility of amendment.” Zucco Partners, LLC v. Digimarc Corp., 552 F.3d 981, 1007 (9th Cir. 2009) (citation omitted). A. Incorporation by Reference Before turning to the merits, the Court first sets the scope of the record on Capital Asset’s motion to dismiss. Normally, courts are limited to materials within the pleadings when deciding motions to dismiss under Rule 12(b)(6). Khoja v. Orexigen Therapeutics, Inc., 899 F.3d 988, 998 (9th Cir. 2018). Capital Asset, however, cites to contract documents that were not attached to the complaint. See Epicrew Contracts, ECF Nos. 14-1, 14-2.2 The Court can consider those contracts only if they are subject to judicial notice or incorporation by reference. Khoja, 899 F.3d at 998. Here, the contracts are incorporated by reference because they “form the basis of” Epicrew’s contract claims; Epicrew alleges that Capital Asset breached those very contracts. Id. at 1002 (citation omitted). Therefore, the Court can consider the contracts. B. Breach of Contract The contracts at issue here are invoices through which Epicrew agreed to purchase certain semiconductor equipment from Capital Asset. See Epicrew Contracts. Epicrew alleges that Capital Asset breached those contracts in three ways: (1) by failing to deliver the promised equipment in a timely manner; (2) purporting to own the equipment when it did not, in violation of Section 5 of the contracts; and (3) violating the implied covenants of good faith and fair dealing. Compl. ¶¶ 37, 44. Capital Asset disputes all three theories of breach. Timely Delivery. Capital Asset argues that the Epicrew Contracts do not contain any provisions setting deadlines for delivery, so it could not have breached the Epicrew Contracts for failing to deliver the promised equipment in a timely manner. Capital Asset is correct that the contracts contain no express timing terms, but its conclusion does not follow. Under California law, “[t]he time for shipment or delivery or any other action under a contract if not . . . agreed upon shall be a reasonable time.” Cal. Com. Code § 2309. Therefore, the Epicrew Contracts contain implied terms that require delivery within a “reasonable time.” Epicrew alleges that it paid for one piece of promised equipment on May 25, 2023, and for the other on December 6, 2023. Compl. ¶¶ 15, 24. Epicrew still has not received either piece of equipment. Drawing all inferences in favor of Epicrew, a delay of well over one year is sufficient to support Epicrew’s claim that Capital Asset failed to timely deliver the promised equipment. Section 5. Section 5 of the Epicrew Contracts reads as follows: “All Equipment is offered to Buyer based on its prior sale to [Capital Asset]. Should such prior sale not occur, this invoice shall be null and void.” On its face, Section 5 does not require Capital Asset to take any action or refrain from taking any action. That is, there is nothing in Section 5 for Capital Asset to breach. If Epicrew is correct that the equipment at issue was not sold to Capital Asset, such fact would not establish a breach. Rather, it would void the Epicrew Contracts. So, Epicrew’s theory of a breach of Section 5 fails. Implied Covenants. Epicrew raises the implied covenants as a theory of its contract claim in addition to raising a standalone claim for breach of the implied covenants. Compl. ¶¶ 37, 44, 49–54. It is not clear whether Epicrew intends to advance different theories for breach of the implied covenants by doing so. Regardless, Epicrew has failed to respond to Capital Asset’s arguments to dismiss the implied covenant claims. See MTD at 6–7; Opp’n, ECF No. 18. By failing to respond to those arguments, Epicrew

Free access — add to your briefcase to read the full text and ask questions with AI

Epicrew USA v. Capital Asset Exchange and Trading, LLC, (N.D. Cal. 2025).

Epicrew USA v. Capital Asset Exchange and Trading, LLC (Epicrew USA v. Capital Asset Exchange and Trading, LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Sandra Omar v. John M. McHugh
646 F.3d 13 (D.C. Circuit, 2011)
Reese v. BP Exploration (Alaska) Inc.
643 F.3d 681 (Ninth Circuit, 2011)
Zucco Partners, LLC v. Digimarc Corp.
552 F.3d 981 (Ninth Circuit, 2009)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Conservation Force v. Salazar
677 F. Supp. 2d 1203 (N.D. California, 2009)
Smith v. Allstate Insurance
160 F. Supp. 2d 1150 (S.D. California, 2001)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Vess v. Ciba-Geigy Corp. USA
317 F.3d 1097 (Ninth Circuit, 2003)